NuLife Shares Details of Proposed Merger

NuLife Sciences (OTCQB:NULF) announced the signing of a letter of intent to undertake a formal merger with Ensysce Biosciences.
As quoted in the press release:

Ensysce’s BIO-MD is a prodrug delivery platform that provides abuse deterrence to a long list of prescription drugs, including opioid products. The prodrugs are activated in a 2-step, enzyme mediated reaction only after oral administration. This process removes the patient’s ability to abuse the drug by inhalation or through kitchen chemistry and intravenous injection. Ensysce has recently completed a Phase 1 trial with its lead oxycodone prodrug, PF614. The trial results in 48 subjects, randomized to receive PF614 or Oxycontin, showed over 90% efficient release of oxycodone and an improved safety profile over OxyContin™.
The merged company will focus on proprietary delivery technologies to combat drug abuse and overdose, particularly with opioids. As prescriptions for opioids have risen sharply over the last two decades, rates of addiction and overdose deaths have dramatically increased. Drug overdose deaths are now the leading cause of accidental death in the U.S., exceeding deaths caused by motor vehicle accidents, guns and HIV infection. The number of overdose deaths involving specifically opioids, including prescription opioids and heroin, has quadrupled since 1999. The epidemic has led to President Trump recently declaring the drug and opioid crisis a national emergency.

Click here to read the full press release.

Source: www.marketwired.com